Coincidence of Bullous Pemphigoid and Pityriasis Rubra Pilaris
DOI:
https://doi.org/10.2340/actadv.v102.1289Keywords:
Bullous pemphigoid, pityriasis rubra pilaris, BP180, LAD-1, intravenous immunoglobulinAbstract
Abstract is missing (Short communication)
Downloads
References
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.
https://doi.org/10.1016/S0140-6736(12)61140-4 DOI: https://doi.org/10.1016/S0140-6736(12)61140-4
Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol 2018; 54: 26-51.
https://doi.org/10.1007/s12016-017-8633-4 DOI: https://doi.org/10.1007/s12016-017-8633-4
Chaudhary R, Chaudhary N. A 45-year-old woman with erythroderma and bullous eruption: erythrodermic bullous pemphigoid. J Pharm Biomed Sci 2018; 8: 94-97.
Genovese G, Muratori S, Berti E, Marzano AV. Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid. Clin Exp Dermatol 2019; 44: 73-75.
https://doi.org/10.1111/ced.13718 DOI: https://doi.org/10.1111/ced.13718
Miyashita K, Iioka H, Miyagawa F, Ishii N, Hashimoto T, Asada H. A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230. Eur J Dermatol 2018: 28: 248-250.
https://doi.org/10.1684/ejd.2018.3229 DOI: https://doi.org/10.1684/ejd.2018.3229
Schulze F, Neumann K, Recke A, Zillikens D, Linder R, Schmidt E. Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol 2015; 135: 1445-1447.
https://doi.org/10.1038/jid.2014.547 DOI: https://doi.org/10.1038/jid.2014.547
Goto-Hamano H, Ito K, Sakamoto-Kumura K, Terui T, Ohyama B, Hashimoto T, Hara H. Autoantibodies against multiple epitopes in Bp180 and laminin gamma-1 in subepidermal blistering skin disease associated with psoriatic erythroderma. Indian J Dermatol 2015; 60: 521.
https://doi.org/10.4103/0019-5154.164433 DOI: https://doi.org/10.4103/0019-5154.164433
Roeder C, Driesch PV. Psoriatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine. Eur J Dermatol 1999; 9: 537-539.
Kerr AC, Ferguson J. Type II adult-onset pityriasis rubra pilaris successfully treated with intravenous immunoglobulin. Br J Dermatol 2007; 156: 1055-1056.
https://doi.org/10.1111/j.1365-2133.2007.07773.x DOI: https://doi.org/10.1111/j.1365-2133.2007.07773.x
Hoffmann JHO, Enk AH. High-Dose Intravenous Immunoglobulin in skin autoimmune disease. Front Immunol 2019; 10: 1090.
https://doi.org/10.3389/fimmu.2019.01090 DOI: https://doi.org/10.3389/fimmu.2019.01090
Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol 2017; 77: 845-854.e5.
https://doi.org/10.1016/j.jaad.2017.07.013 DOI: https://doi.org/10.1016/j.jaad.2017.07.013
Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844-854.
https://doi.org/10.1111/bjd.12214 DOI: https://doi.org/10.1111/bjd.12214
Published
How to Cite
License
Copyright (c) 2022 Irina Gasslitter, Judith Löffler-Ragg, Enno Schmidt, Matthias Schmuth, Robert Gruber
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
